Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

Related Articles by Review for PubMed (Select 22729452)

1.

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW.

Rev Bras Psiquiatr. 2012 Jun;34 Suppl 1:S104-10. Review. English, Portuguese.

2.

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS.

Braz J Med Biol Res. 2006 Apr;39(4):421-9. Epub 2006 Apr 3. Review.

3.

Safety and side effects of cannabidiol, a Cannabis sativa constituent.

Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA.

Curr Drug Saf. 2011 Sep 1;6(4):237-49. Review.

PMID:
22129319
4.

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Zuardi AW.

Rev Bras Psiquiatr. 2008 Sep;30(3):271-80. Review.

5.

Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

Sarris J, McIntyre E, Camfield DA.

CNS Drugs. 2013 Apr;27(4):301-19. doi: 10.1007/s40263-013-0059-9. Review. Erratum in: CNS Drugs. 2013 Aug;27(8):675. Dosage error in article text.

PMID:
23653088
6.

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.

de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, Machado S, Arias-Carrión O, Crippa JA, Zuardi AW, Nardi AE, Silva AC.

CNS Neurol Disord Drug Targets. 2014;13(6):953-60. Review.

PMID:
24923339
7.

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78. doi: 10.1098/rstb.2011.0389. Review.

8.

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS.

Curr Pharm Des. 2012;18(32):5131-40. Review.

PMID:
22716160
9.

Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders.

Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G.

Phytother Res. 2009 May;23(5):597-602. doi: 10.1002/ptr.2625. Review.

PMID:
18844286
10.

Cannabidiol as a potential treatment for psychosis.

Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP.

Eur Neuropsychopharmacol. 2014 Jan;24(1):51-64. doi: 10.1016/j.euroneuro.2013.11.002. Epub 2013 Nov 15. Review.

PMID:
24309088
11.

Does Cannabidiol Protect Against Adverse Psychological Effects of THC?

Niesink RJ, van Laar MW.

Front Psychiatry. 2013 Oct 16;4:130. doi: 10.3389/fpsyt.2013.00130. Review.

12.

[Treatment of generalized anxiety: new pharmacologic approaches].

Boulenger JP.

Encephale. 1995 Nov-Dec;21(6):459-66. Review. French.

PMID:
8674471
13.

Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects.

Mechoulam R, Hanus L.

Chem Phys Lipids. 2002 Dec 31;121(1-2):35-43. Review.

PMID:
12505688
14.

Antidepressant treatment in anxiety disorders.

Bespalov AY, van Gaalen MM, Gross G.

Curr Top Behav Neurosci. 2010;2:361-90. Review.

PMID:
21309117
15.

Animal models of anxiety: are they suitable for predicting drug action in humans?

Bourin M.

Pol J Pharmacol. 1997 Mar-Jun;49(2-3):79-84. Review.

PMID:
9437753
16.

Placebo response in anxiety disorders.

Piercy MA, Sramek JJ, Kurtz NM, Cutler NR.

Ann Pharmacother. 1996 Sep;30(9):1013-9. Review.

PMID:
8876864
17.

Spotlight on paroxetine in psychiatric disorders in adults.

Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL.

CNS Drugs. 2002;16(6):425-34. Review.

PMID:
12027788
18.

Cannabidiol: an overview of some pharmacological aspects.

Mechoulam R, Parker LA, Gallily R.

J Clin Pharmacol. 2002 Nov;42(11 Suppl):11S-19S. Review.

PMID:
12412831
19.

Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.

Roser P, Vollenweider FX, Kawohl W.

World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):208-19. doi: 10.3109/15622970801908047. Review.

PMID:
20218784
20.

[Anxiety and the mechanisms of action of anxiolytics].

Marino A, Costa R.

Recenti Prog Med. 1993 Feb;84(2):129-41. Review. Italian.

PMID:
8096650
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk